Byron K. Peters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Byron K. Peters has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Pher G. Andersson
Department of Organic Chemistry Stockholm University 10691 Stockholm Sweden
8 shared publications - Thavendran Govender
Department of Chemistry, University of Zululand, Private Bag X1001, Kwadlangezwa 3886, South Africa
6 shared publications - Hendrik Gerhardus Kruger
University of KwaZulu-Natal
4 shared publications - Phil S. Baran
Department of Chemistry, Scripps Research, La Jolla, USA
3 shared publications Taigang Zhou
Department of Organic Chemistry, Stockholm University, S-10691 Stockholm, Sweden
3 shared publications- Tricia Naicker
University of KwaZulu-Natal
3 shared publications
Latest Publications
- 27 October 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Development of a Continuous Trickle-Flow Hydrogenation Process for Cbz Deprotection in Dipeptide Synthesis
The synthesis of enlicitide decanoate (MK-0616), a first-in-class oral PCSK9 inhibitor, requires efficient Cbz deprotection of a proline–threonine dipeptide intermediate, presenting safety and economic challenges for traditional batch hydrogenation. Here, we report the development of a continuous trickle-bed flow reactor with customized components that addresses these manufacturing constraints through systematic process optimization. This paper reports the development of a laboratory-scale trickle-bed flow reactor with customized components on a commercially available system along with catalyst characterization and continuous temperature mapping. The optimized process achieved complete conversion with 3.8% catalyst loading (24% reduction versus batch processing) and maintained a robust performance over extended operations. This comprehensive development establishes a scalable, safer alternative to batch hydrogenation while reducing precious-metal usage, providing a template for pharmaceutical flow chemistry applications requiring heterogeneous catalysis.
- 27 October 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Development of a Continuous Trickle-Flow Hydrogenation Process for Cbz Deprotection in Dipeptide Synthesis
The synthesis of enlicitide decanoate (MK-0616), a first-in-class oral PCSK9 inhibitor, requires efficient Cbz deprotection of a proline–threonine dipeptide intermediate, presenting safety and economic challenges for traditional batch hydrogenation. Here, we report the development of a continuous trickle-bed flow reactor with customized components that addresses these manufacturing constraints through systematic process optimization. This paper reports the development of a laboratory-scale trickle-bed flow reactor with customized components on a commercially available system along with catalyst characterization and continuous temperature mapping. The optimized process achieved complete conversion with 3.8% catalyst loading (24% reduction versus batch processing) and maintained a robust performance over extended operations. This comprehensive development establishes a scalable, safer alternative to batch hydrogenation while reducing precious-metal usage, providing a template for pharmaceutical flow chemistry applications requiring heterogeneous catalysis.
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- 31 August 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (9) , 2540-2548
Synthesis of N -Linked Amino-Hexyl Fluorotryptophan for Enlicitide, Part 2: Process Improvements toward Commercial Manufacture
Herein, we report the development of a robust manufacturing process for N-linked amino-hexyl fluorotryptophan 3, a key building block for enlicitide decanoate (MK-0616), which is an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Targeted process development enabled safe operation of the Delépine reaction, increased yields for the hexamine hydrolysis and enzymatic tryptophan synthesis, and established a robust and selective N-alkylation of 5-fluorotryptophan. Collectively, these improvements afforded the target product with high yield, >98.5% purity, and favorable physical properties suitable for commercial manufacture.
- Top Cited Papers
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- 7 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6798) , 643-647
Top Cited PapersBiocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.
- Open Access
- 14 February 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (3) , 486-496
In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
β-lactams are the most prescribed class of antibiotics due to their potent, broad-spectrum antimicrobial activities. However, alarming rates of antimicrobial resistance now threaten the clinical relevance of these drugs, especially for the carbapenem-resistant Enterobacterales expressing metallo-β-lactamases (MBLs). Antimicrobial agents that specifically target these enzymes to restore the efficacy of last resort β-lactam drugs, that is, carbapenems, are therefore desperately needed. Herein, we present a cyclic zinc chelator covalently attached to a β-lactam scaffold (cephalosporin), that is, BP1. Observations from in vitro assays (with seven MBL expressing bacteria from different geographies) have indicated that BP1 restored the efficacy of meropenem to ≤ 0.5 mg/L, with sterilizing activity occurring from 8 h postinoculation. Furthermore, BP1 was nontoxic against human hepatocarcinoma cells (IC50 > 1000 mg/L) and exhibited a potency of (Kiapp) 24.8 and 97.4 μM against Verona integron-encoded MBL (VIM-2) and New Delhi metallo β-lactamase (NDM-1), respectively. There was no inhibition observed from BP1 with the human zinc-containing enzyme glyoxylase II up to 500 μM. Preliminary molecular docking of BP1 with NDM-1 and VIM-2 sheds light on BP1's mode of action. In Klebsiella pneumoniae NDM infected mice, BP1 coadministered with meropenem was efficacious in reducing the bacterial load by >3 log10 units' postinfection. The findings herein propose a favorable therapeutic combination strategy that restores the activity of the carbapenem antibiotic class and complements the few MBL inhibitors under development, with the ultimate goal of curbing antimicrobial resistance.
- 14 February 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (3) , 486-496
Open AccessIn Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
β-lactams are the most prescribed class of antibiotics due to their potent, broad-spectrum antimicrobial activities. However, alarming rates of antimicrobial resistance now threaten the clinical relevance of these drugs, especially for the carbapenem-resistant Enterobacterales expressing metallo-β-lactamases (MBLs). Antimicrobial agents that specifically target these enzymes to restore the efficacy of last resort β-lactam drugs, that is, carbapenems, are therefore desperately needed. Herein, we present a cyclic zinc chelator covalently attached to a β-lactam scaffold (cephalosporin), that is, BP1. Observations from in vitro assays (with seven MBL expressing bacteria from different geographies) have indicated that BP1 restored the efficacy of meropenem to ≤ 0.5 mg/L, with sterilizing activity occurring from 8 h postinoculation. Furthermore, BP1 was nontoxic against human hepatocarcinoma cells (IC50 > 1000 mg/L) and exhibited a potency of (Kiapp) 24.8 and 97.4 μM against Verona integron-encoded MBL (VIM-2) and New Delhi metallo β-lactamase (NDM-1), respectively. There was no inhibition observed from BP1 with the human zinc-containing enzyme glyoxylase II up to 500 μM. Preliminary molecular docking of BP1 with NDM-1 and VIM-2 sheds light on BP1's mode of action. In Klebsiella pneumoniae NDM infected mice, BP1 coadministered with meropenem was efficacious in reducing the bacterial load by >3 log10 units' postinfection. The findings herein propose a favorable therapeutic combination strategy that restores the activity of the carbapenem antibiotic class and complements the few MBL inhibitors under development, with the ultimate goal of curbing antimicrobial resistance.
- 1 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (50) , 20979-20986
Electroreductive Olefin–Ketone Coupling
A user-friendly approach is presented to sidestep the venerable Grignard addition to unactivated ketones to access tertiary alcohols by reversing the polarity of the disconnection. In this work a ketone instead acts as a nucleophile when adding to simple unactivated olefins to accomplish the same overall transformation. The scope of this coupling is broad as enabled using an electrochemical approach, and the reaction is scalable, chemoselective, and requires no precaution to exclude air or water. Multiple applications demonstrate the simplifying nature of the reaction on multistep synthesis, and mechanistic studies point to an intuitive mechanism reminiscent of other chemical reductants such as SmI2 (which cannot accomplish the same reaction).
- 1 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (50) , 20979-20986
Electroreductive Olefin–Ketone Coupling
A user-friendly approach is presented to sidestep the venerable Grignard addition to unactivated ketones to access tertiary alcohols by reversing the polarity of the disconnection. In this work a ketone instead acts as a nucleophile when adding to simple unactivated olefins to accomplish the same overall transformation. The scope of this coupling is broad as enabled using an electrochemical approach, and the reaction is scalable, chemoselective, and requires no precaution to exclude air or water. Multiple applications demonstrate the simplifying nature of the reaction on multistep synthesis, and mechanistic studies point to an intuitive mechanism reminiscent of other chemical reductants such as SmI2 (which cannot accomplish the same reaction).
- 1 March 2019
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 30 (10) , 1178-1182
Electrochemical C(sp3)–H Fluorination
A simple and robust method for electrochemical alkyl C–H fluorination is presented. Using a simple nitrate additive, a widely available fluorine source (Selectfluor), and carbon-based electrodes, a wide variety of activated and unactivated C–H bonds are converted into their C–F congeners. The scalability of the reaction is also demonstrated with a 100 gram preparation of fluorovaline.
- 1 March 2019
- Published by Georg Thieme Verlag KG in Synlett
- Vol. 30 (10) , 1178-1182
Electrochemical C(sp3)–H Fluorination
A simple and robust method for electrochemical alkyl C–H fluorination is presented. Using a simple nitrate additive, a widely available fluorine source (Selectfluor), and carbon-based electrodes, a wide variety of activated and unactivated C–H bonds are converted into their C–F congeners. The scalability of the reaction is also demonstrated with a 100 gram preparation of fluorovaline.
- Top Cited Papers
- 22 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 363 (6429) , 838-845
Scalable and safe synthetic organic electroreduction inspired by Li-ion battery chemistry
Scaled-up sodium-free Birch reductions: The so-called Birch reduction is frequently used by chemists despite its daunting conditions: Pyrophoric sodium is dissolved in pure liquified ammonia to achieve partial reduction of aromatics. Peters et al. surveyed and then optimized small-scale electrochemical alternatives to devise a safer protocol that can work on a larger scale with a broad range of functionally complex substrates. Science , this issue p. 838
- 22 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 363 (6429) , 838-845
Top Cited PapersScalable and safe synthetic organic electroreduction inspired by Li-ion battery chemistry
Scaled-up sodium-free Birch reductions: The so-called Birch reduction is frequently used by chemists despite its daunting conditions: Pyrophoric sodium is dissolved in pure liquified ammonia to achieve partial reduction of aromatics. Peters et al. surveyed and then optimized small-scale electrochemical alternatives to devise a safer protocol that can work on a larger scale with a broad range of functionally complex substrates. Science , this issue p. 838
- Open Access
- 19 December 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (1) , 190-193
An unexpected re-arrangement of the antibiotic carbapenem core to new 1,4-diazepin-5-one scaffolds
Herein we report a peculiar organocatalyzed domino-reaction on the carbapenem core structure. As previously reported, 30 mol% of proline yields diazabicyclo[4.2.1]nonane analogues, while we currently report the formation of novel 1,4-diazepin-5-ones from the same starting material in the presence of 100 mol% proline. The inherent chirality of the starting material led to the stereochemical preference of the products with excellent diastereoselectivity (>99 : 1). The diazepinone products were confirmed using X-ray diffraction and 2D-NMR structure elucidation. A plausible mechanism of the re-arrangement, involving an unactivated retro-Dieckmann condensation, is also presented.
- 19 December 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (1) , 190-193
Open AccessAn unexpected re-arrangement of the antibiotic carbapenem core to new 1,4-diazepin-5-one scaffolds
Herein we report a peculiar organocatalyzed domino-reaction on the carbapenem core structure. As previously reported, 30 mol% of proline yields diazabicyclo[4.2.1]nonane analogues, while we currently report the formation of novel 1,4-diazepin-5-ones from the same starting material in the presence of 100 mol% proline. The inherent chirality of the starting material led to the stereochemical preference of the products with excellent diastereoselectivity (>99 : 1). The diazepinone products were confirmed using X-ray diffraction and 2D-NMR structure elucidation. A plausible mechanism of the re-arrangement, involving an unactivated retro-Dieckmann condensation, is also presented.
- 2 September 2016
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 138 (36) , 11930-11935
Enantio- and Regioselective Ir-Catalyzed Hydrogenation of Di- and Trisubstituted Cycloalkenes
A number of cyclic olefins were prepared and evaluated for the asymmetric hydrogenation reaction using novel N,P-ligated iridium imidazole-based catalysts (Crabtree type). The diversity of these cyclic olefins spanned those having little functionality to others bearing strongly coordinating substituents and heterocycles. Excellent enantioselectivities were observed both for substrates having little functionality (up to >99% ee) and for substrates possessing functional groups several carbons away from the olefin. Substrates having functionalities such as carboxyl groups, alcohols, or heterocycles in the vicinity of the C═C bond were hydrogenated in high enantiomeric excess (up to >99% ee). The hydrogenation was also found to be regioselective, and by controlling the reaction conditions, selective hydrogenation of one of two trisubstituted olefins can be achieved. Furthermore, trisubstituted olefins can be selectively hydrogenated in the presence of tetrasubstituted olefins.
- 2 September 2016
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 138 (36) , 11930-11935
Enantio- and Regioselective Ir-Catalyzed Hydrogenation of Di- and Trisubstituted Cycloalkenes
A number of cyclic olefins were prepared and evaluated for the asymmetric hydrogenation reaction using novel N,P-ligated iridium imidazole-based catalysts (Crabtree type). The diversity of these cyclic olefins spanned those having little functionality to others bearing strongly coordinating substituents and heterocycles. Excellent enantioselectivities were observed both for substrates having little functionality (up to >99% ee) and for substrates possessing functional groups several carbons away from the olefin. Substrates having functionalities such as carboxyl groups, alcohols, or heterocycles in the vicinity of the C═C bond were hydrogenated in high enantiomeric excess (up to >99% ee). The hydrogenation was also found to be regioselective, and by controlling the reaction conditions, selective hydrogenation of one of two trisubstituted olefins can be achieved. Furthermore, trisubstituted olefins can be selectively hydrogenated in the presence of tetrasubstituted olefins.
- 17 March 2015
- Published by Wiley in Chemistry – A European Journal
- Vol. 21 (19) , 7292-7296
Formal Total Synthesis of Aliskiren
The efficient and selective formal total synthesis of aliskiren is described. Aliskiren, a renin inhibitor drug, has received considerable attention, primarily because it is the first of the renin inhibitor drugs to be approved by the FDA. Herein, the formal synthesis of aliskiren by iridium‐catalyzed asymmetric hydrogenation of two allylic alcohol fragments is reported. Screening a number of N,P‐ligated iridium catalysts yielded two catalysts that gave the highest enantioselectivity in the hydrogenation, which gave the saturated alcohols in 97 and 93 %ee. In only four steps after hydrogenation, the fragments were combined by using the Julia–Kocienski reaction to produce late‐stage intermediate in an overall yield of 18 %.
- 17 March 2015
- Published by Wiley in Chemistry – A European Journal
- Vol. 21 (19) , 7292-7296
Formal Total Synthesis of Aliskiren
The efficient and selective formal total synthesis of aliskiren is described. Aliskiren, a renin inhibitor drug, has received considerable attention, primarily because it is the first of the renin inhibitor drugs to be approved by the FDA. Herein, the formal synthesis of aliskiren by iridium‐catalyzed asymmetric hydrogenation of two allylic alcohol fragments is reported. Screening a number of N,P‐ligated iridium catalysts yielded two catalysts that gave the highest enantioselectivity in the hydrogenation, which gave the saturated alcohols in 97 and 93 %ee. In only four steps after hydrogenation, the fragments were combined by using the Julia–Kocienski reaction to produce late‐stage intermediate in an overall yield of 18 %.